Vivus

From Wikipedia, the free encyclopedia

Vivus (NASDAQ: VVUS) is a small pharmaceutical company headquartered in Mountain View, California, working in obesity, sleep, and sexual health. Vivus is developing an erectile dysfunction drug, Avanafil, that has completed Phase 3 clinical trials.[1] The drug has been approved for use by the FDA, and will be sold under the trademark name Stendra[2]

A documentary movie "Orgasm Inc." was made at Vivus in 2009 to document the process of creating a treatment for Female sexual arousal disorder (FSD).

Vivus also developed an obesity drug, Qnexa (now called Qsymia), a combination of phentermine and topiramate, two existing weight-loss drugs.[3] On July 17, 2012, The U.S. Food and Drug Administration approved Qsymia (phentermine and topiramate extended-release), made by Vivus, as an addition to a reduced-calorie diet and exercise for chronic weight management. The drug was approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).[4][5]


References

  1. ↑ Phase 3 Data on VIVUS' Avanafil for Erectile Dysfunction to be Featured at the AUA 2010 Annual Meeting, ""
  2. ↑
  3. ↑ Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP), ""
  4. ↑ Hellmich, Nancy. "New diet drug helps patients lose about 10% of weight". USA Today. Retrieved 17 July 2012. 
  5. ↑ "Medications Target Long-Term Weight Control". FDA.gov. Retrieved 17 July 2012. 

External links


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.